Loading
JSKN016 is an experimental drug that targets two proteins on cancer cells and carries chemotherapy. It has reached phase 3 testing; earlier response findings do not prove comparative benefit.
JSKN016 targets TROP2 and HER3. SABCS 2025 abstract PS1-09-05 reports an uncontrolled phase I breast cohort at the September 5, 2025 cutoff: 82 enrolled patients, including 50 with TNBC and 32 with HR-positive/HER2-negative disease. Among 47 efficacy-evaluable TNBC patients, ORR was 57.4% by investigators and 63.8% by independent review. Median follow-up was 5.0 months. Grade 3 neutropenia occurred in 4.9% of the breast cohort; no interstitial lung disease was reported in that abstract. NCT07533123 separately registers phase 3 testing in previously treated TNBC. Its highest registered phase is not the evidence level of the phase I response estimate.
1.JSKN016's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JSKN016" OR ABSTRACT:"JSKN016") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JSKN016, not a curated reading list.
Shares TROP2, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares TROP2, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares HER3, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER3, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Alphamab Oncology and the tag pipeline.
Shares TROP2, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares TROP2, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares TROP2, Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/